Table 3.
Common toxicities associated with docetaxel
| Trial | Chan et al23 | BCIRG-00129 | BIG 02-9830 | E291731 | BCIRG-00644 |
|---|---|---|---|---|---|
| Dose administered | 100 mg/m2 | 75 mg/m2 | 50–100 mg/m2 | 60 mg/m2 | 75–100 mg/m2 |
| Setting | Metastatic | Adjuvant | Adjuvant | Adjuvant | Adjuvant |
| Neutropenia (grade 3–4) | 93.5% | 65.6% (P < 0.001) | 28% | 54% (P < 0.05) | 65.9% |
| Fluid retention | 59.7% | 33.7% (P < 0.001) | 0.3% | ||
| Neurosensory disorders | 42.8% (P ≤ 0.05) | 25.5% (P < 0.001) | 0.8% | 1% | 36% |
| Diarrhea | 50.3% (P ≤ 0.05) | 35.2% | 6% | 5% | 5.4% |
| Nail disorder | 44% (P ≤ 0.05) | 18.5% | NA | 28.7% |